Table 5 Baseline characteristics
Variable | Type of variable |
|---|---|
Age (years) | Continuous |
Age (by EudraCT reporting categories) | Categorical (18–64, 65–84, 85 +) |
Sex | Categorical (M/F) |
MND subtype | Categorical (amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, other) |
Site of onset | Categorical (bulbar, spinal, respiratory, other) |
El Escorial Criteria Level | Categorical (suspected, probable, probable laboratory supported, definite, possible, other, not applicable) |
Symptom duration (time since first symptom) | Continuous |
Time since diagnosis (time since date of diagnosis) | Continuous |
Long survivor (> 8 years since diagnosis) | Categorical (Y/N) |
Genetic (%) | Categorical (% of pts with known genetic cause) |
Riluzole use | Categorical (Y/N) |
NIV and/or gastrostomy | Categorical (Y/N) |
ALS-FRS-R | Continuous (total score) |
FVC | Continuous |
King’s stage | Categorical (1, 2, 3, 4) |
EQ-5D-5L | Continuous (index and VAS) |
HADS | Continuous (including anxiety and depression subscales, and overall score) |
ECAS | Continuous (total participant score, participant score stratified by domains, total carer score) |